olivLaw · US equity research
Armata Pharmaceuticals, Inc. ARMP
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Armata Pharmaceuticals develops high-purity bacteriophage therapies for antibiotic-resistant bacterial infections, with its lead focus being AP-SA02 for Staphylococcus aureus bacteremia, which is preparing for a pivotal Phase 3 study in the second half of 2026. The company remains dependent on additional funding, and its liquidity at the end of 2025 was only 8.7 million USD.
At the close of 30 Oct 2026, Armata Pharmaceuticals, Inc. (ARMP) stock was 3.28 USD (+0.92% on the day), with market capitalisation 122.0 m USD, beta 0.23, 52-week range 2.78–14.80 USD. Latest reported quarter (Q2 2026): net income of 74.1 m USD, diluted EPS -0.27 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 43.8
- weak (30–45)
- Bollinger (20, 2)
- 2.81 – 3.98
- in the lower half of the band · %B 0.40 · band width 34.4%
- SMA 50 / 200
- 4.18 / 7.01
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.20 / -0.26
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.6% | −0.9% | −9.7 pp | — |
| 3 months | −27.8% | +1.2% | −29.0 pp | — |
| 6 months | −63.1% | +4.8% | −67.9 pp | — |
| Year to date | −47.8% | +10.7% | −58.5 pp | — |
| 1 year | −33.9% | +11.1% | −45.0 pp | −7.9% |
| 3 years | +45.8% | +80.7% | −35.0 pp | −4.8% |
| 5 years | +2.5% | +64.6% | −62.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -9.8 m | -10.5 m | -8.2 m | -6.8 m | -7.8 m | -13.8 m | -8.8 m | -10.3 m |
| Depreciation & amortisation | 313.0 k ≈ | 380.0 k | 377.0 k | 366.0 k ≈ | 370.0 k ≈ | — | — | — |
| Income tax | 0 | — | 0 | 0 ≈ | 0 | — | 0 | 0 ≈ |
| Net income | -5.5 m | 2.6 m | -6.5 m | -16.3 m | -26.7 m | -124.3 m | -115.3 m | 74.1 m |
| Diluted EPS | -0.15 | 0.02 ≈ | -0.20 | -0.45 | -0.74 | -3.42 ≈ | -3.16 | -0.27 |
| Operating cash flow | -8.9 m ≈ | -7.9 m | -7.6 m | -7.2 m ≈ | -4.3 m ≈ | -6.7 m | -5.8 m | -8.7 m ≈ |
| Capex | 340.0 k ≈ | -77.0 k | 99.0 k | 149.0 k ≈ | 242.0 k ≈ | 52.0 k | 63.0 k | 17.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -16.7 m | -19.5 m | -22.2 m | -23.2 m | -36.9 m | -69.0 m | -18.9 m | -173.8 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -3.59 | -2.55 | -1.35 | -0.96 | -1.08 | -1.91 | -0.89 | -4.80 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -11.5 m | -15.8 m | -19.1 m | -24.9 m | -34.7 m | -55.6 m | -39.4 m | -26.3 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 8.7 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- -218.6 m USD
- Total assets
- 76.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.19x
- ROE
- unavailable
- ROA
- -212.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating income | -21.6 m | -23.8 m | -36.9 m | -40.9 m | -42.4 m | -36.6 m | SEC (XBRL)· 25 Mar 2026verified |
| Depreciation & amortisation | — | — | 892.0 k | 972.0 k | 1.3 m | — | SEC (XBRL)· 21 Mar 2025verified |
| EBITDA | — | — | -36.1 m ≈ | -39.9 m ≈ | -41.1 m ≈ | — | SEC (XBRL)· 21 Mar 2025derived |
| Interest expense | 628.0 k | 64.0 k | 0 | 2.6 m | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Pre-tax income | -22.2 m | -23.2 m | -36.9 k | -69.0 m | -18.9 m | -173.8 m | SEC (XBRL)· 25 Mar 2026verified |
| Net income | -22.2 m | -23.2 m | -36.9 m | -69.0 m | -18.9 m | -173.8 m | SEC (XBRL)· 25 Mar 2026verified |
| Diluted EPS | -1.35 | -0.96 | -1.08 | -1.91 | -0.89 | -4.80 | SEC (XBRL)· 25 Mar 2026verified |
| Weighted average diluted shares | 16.4 m | 24.1 m | 34.3 m | 36.1 m | 59.1 m | 36.2 m | SEC (XBRL)· 25 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 9.6 m | 10.3 m | 14.9 m | 13.5 m | 9.3 m | 8.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Current assets | 10.8 m | 15.0 m | 27.0 m | 19.2 m | 11.3 m | 10.7 m | SEC (XBRL)· 25 Mar 2026verified |
| Property, plant & equipment, net | 2.0 m | 2.2 m | 3.6 m | 12.6 m | 13.2 m | 12.2 m | SEC (XBRL)· 25 Mar 2026verified |
| Goodwill | 3.5 m | 3.5 m | 3.5 m | 3.5 m | 3.5 m | 3.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Intangibles (excl. goodwill) | 10.3 m | 10.3 m | 10.3 m | 10.3 m | 10.3 m | 10.3 m | SEC (XBRL)· 25 Mar 2026verified |
| Total assets | 39.5 m | 69.8 m | 95.8 m | 98.4 m | 86.4 m | 76.9 m | SEC (XBRL)· 25 Mar 2026verified |
| Accounts payable | 956.0 k | 1.1 m | 1.7 m | 1.6 m | 766.0 k | 921.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Current liabilities | 6.7 m | 4.8 m | 24.9 m | 16.5 m | 48.2 m | 8.9 m | SEC (XBRL)· 25 Mar 2026verified |
| Total liabilities | 20.7 m | 44.4 m | 59.8 m | 130.4 m | 134.5 m | 295.5 m | SEC (XBRL)· 25 Mar 2026verified |
| Equity | 18.9 m † | 25.4 m † | 36.1 m † | -32.1 m † | -48.0 m † | -218.6 m † | SEC (XBRL)· 25 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -18.3 m | -23.6 m | -32.5 m | -47.4 m | -37.6 m | -25.8 m | SEC (XBRL)· 25 Mar 2026verified |
| Capex | 824.0 k | 1.3 m | 2.2 m | 8.1 m | 1.9 m | 542.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Free cash flow | -19.1 m ≈ | -24.9 m ≈ | -34.7 m ≈ | -55.6 m ≈ | -39.4 m ≈ | -26.3 m ≈ | SEC (XBRL)· 25 Mar 2026derived |
| Investing cash flow | -824.0 k | -1.3 m | -2.2 m | -8.1 m | -1.9 m | -542.0 k | SEC (XBRL)· 25 Mar 2026verified |
| Financing cash flow | 23.2 m | 25.5 m | 44.0 m | 54.0 m | 35.0 m | 25.6 m | SEC (XBRL)· 25 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 12.5% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
30 Oct 2026Source: olivLaw, closing series
Market cap: 122.0 m USD
Key indicators
Coverage and freshness
Score by group
13% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.1x | 0 (on a fixed band) | 33% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -21.2% | 0 (on a fixed band) | 67% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial0/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ARMATA PHARMACEUTICALS, INC. (ARMP). Latest full fiscal year: 2025; data up to 2026-06-30.
Financial indicators are unavailable.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 12.5% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Current ratio: 0.1x
- FCF yield: -21.2%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 251.9 bn | 28.9 | 91.5% | 23.0% | +10.0% | +56% / +82% |
| GILDGilead Sciences, Inc. | 211.7 bn | — | -22.3% | -12.5% | +2.4% | +42% / +117% |
| MRNAModerna, Inc. | 88.5 bn | — | -39.0% | -141.4% | −39.9% | +716% / +192% |
| RVMDRevolution Medicines, Inc. | 41.0 bn | — | -79.1% | — | unavailable | +225% / +866% |
| BIIBBiogen Inc. | 37.5 bn | 108.4 | 1.9% | 3.4% | +2.2% | +64% / +7% |
| EXELExelixis, Inc. | 16.9 bn | 20.7 | 44.3% | 35.5% | +7.0% | +79% / +237% |
| KRYSKrystal Biotech, Inc. | 9.8 bn | 41.7 | 20.1% | 54.8% | +33.9% | +68% / +184% |
| SCNIScinai Immunotherapeutics Ltd. | 6.5 bn | — | -91.9% | -633.6% | +99.2% | −97% / −99% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.2 bn | — | — | -40.9% | +94.1% | +16% / +54% |
| NVAXNovavax Inc | 1.7 bn | — | — | -59.9% | +64.7% | +20% / +51% |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −49% / −95% |
| GLUEMonte Rosa Therapeutics, Inc. | 918.0 m | — | -42.7% | -560.9% | +63.5% | −16% / +216% |
| SLDBSolid Biosciences Inc. | 664.8 m | — | -65.5% | — | −40.6% | +15% / +178% |
| FDMT4D Molecular Therapeutics, Inc. | 592.4 m | — | -43.3% | -194.7% | +230,194.6% | +3% / +11% |
| CCCCC4 Therapeutics, Inc. | 414.6 m | — | -48.1% | -289.4% | +1.0% | +29% / +126% |
| EDITEditas Medicine, Inc. | 410.1 m | — | -118.8% | -157.3% | +25.4% | −13% / −60% |
| ALLOAllogene Therapeutics, Inc. | 407.7 m | — | -42.4% | -3,566.7% | −100.0% | −5% / −58% |
| AUTLAutolus Therapeutics plc | 404.6 m | — | -133.0% | -238.7% | +644.9% | −2% / −46% |
| IPSCCentury Therapeutics, Inc. | 266.2 m | — | -49.7% | -100.6% | +1,556.8% | +152% / −4% |
| PLXProtalix BioTherapeutics, Inc. | 208.7 m | 11.2 | 31.2% | 23.5% | −1.2% | +9% / +55% |
| CGENCompugen Ltd | 187.2 m | 5.2 | 44.8% | 48.6% | +161.1% | +12% / +161% |
| TARAProtara Therapeutics, Inc. | 146.6 m | — | -45.8% | — | unavailable | −52% / +99% |
| CHRSCoherus Oncology, Inc. | 128.2 m | — | -146.3% | -259.4% | +59.8% | −51% / −75% |
| ARMPArmata Pharmaceuticals, Inc. | 122.0 m | — | — | — | unavailable | −34% / +46% |
| LENZLenz Therapeutics, Inc. | 95.8 m | — | -59.2% | -586.7% | unavailable | −90% / −83% |
1- and 3-year price returns: for ARMP from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Armata Pharmaceuticals develops high-purity bacteriophage therapies for antibiotic-resistant bacterial infections, with its lead focus being AP-SA02 for Staphylococcus aureus bacteremia, which is preparing for a pivotal Phase 3 study in the second half of 2026. The company remains dependent on additional funding, and its liquidity at the end of 2025 was only 8.7 million USD 1.
SWOT
Strengths
- The company has completed three Phase 2 clinical trials and has proprietary cGMP phage manufacturing that supports lot-to-lot consistency 1.
- The Fast Track status and FDA agreement on the pediatric plan could accelerate the path to approval for AP-SA02 3.
- Non-dilutive funding from partners in the defense sector supports preparation for the Phase 3 study 3.
Weaknesses
- The company has recurring losses and negative operating cash flow, and its financial statements flag substantial doubt about its ability to continue as a going concern 1.
- Significant term loans with maturities in 2027 and 2029 limit financial flexibility 1.
- The principal stockholder owns more than half of the shares, which may shape decisions in ways that differ from other stockholders' interests 1.
Opportunities
Threats
- If financing is not obtained in time, development could be delayed or stopped, according to the company's warnings 1.
- The novelty of the phage approach makes it hard to predict development costs and timing, and no phage product has yet been approved 1.
- Policy changes or interruption of government funding could affect the company's programs 1.
Risks
- Going concernhigh
The audit flagged substantial doubt about the ability to continue as a going concern, which could limit access to financing.
- Need for additional capitalhigh
Development of AP-SA02 and the Phase 3 study require substantial funds, and failure to raise them could lead to scaled-back programs 13.
- Small early-stage data setsmedium
Results from Phase 1 and 2 studies with small patient numbers could fail to hold up in larger trials.
- Reliance on third partiesmedium
The company relies on third parties for clinical trials and materials, and their delays could postpone development 1.
- Control by principal stockholderlow
The majority stockholder could have interests that differ from other stockholders, which may influence company decisions 1.
Investment thesis
What would need to be true (bull case)
- If the Phase 3 study confirms the superiority of AP-SA02, the company could become the first to bring an intravenous phage to market for a systemic infection.
- The Fast Track status and the agreed pediatric plan could shorten the path to approval and broaden indications 3.
- Three completed Phase 2 studies and in-house manufacturing capabilities could reduce the technical risk of development 1.
What would break the thesis
- Low liquidity and recurring losses could force shareholder dilution or a delay of Phase 3.
- With no approved product, the company depends entirely on future clinical results, which are uncertain.
- The accounting gains in the second quarter of 2026 came largely from non-cash changes in the value of a convertible loan, not from operations 3.
What to watch
- Start of the Phase 3 study for AP-SA02second half of 2026
- Raising additional funding, including new DoW programs or partnerships2026
- Trend in liquidity and debt, including loan maturities2027
- Decision on resuming AP-PA02 development for non-cystic fibrosis bronchiectasisnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Armata is a late clinical-stage biotechnology company developing bacteriophage therapies specific to pathogens, aimed at treating hard-to-treat infections resistant to antibiotics 1. The company combines its own approach to identifying and characterizing bacteriophages with proprietary phage-specific cGMP manufacturing to support a pipeline of high-quality clinical candidates 1. It is headquartered in Los Angeles and its shares trade on NYSE American under the symbol ARMP 2.
Segments
AP-SA02 (Staphylococcus aureus)
The lead candidate for complicated S. aureus bacteremia, given intravenously. The Phase 1b/2a diSArm study showed a higher clinical response versus placebo, and the FDA confirmed advancement to Phase 3 and granted Fast Track status in 2026 13.
AP-PA02 (Pseudomonas aeruginosa)
An inhaled candidate for chronic pulmonary infections with P. aeruginosa. It was tested in the SWARM-P.a. study in cystic fibrosis patients and the Tailwind study in non-cystic fibrosis bronchiectasis patients, but further clinical development depends on additional funding 1.
Market context
The targeted market is that of antibiotic-resistant bacterial infections, a growing worldwide threat that the company describes as the reason phages could become an alternative to broad-spectrum antibiotics 1. The company argues that new treatments are needed for S. aureus bacteremia, a condition associated with high morbidity and mortality 3.
Trends
- Rising antibiotic resistancetailwind
Growing bacterial resistance to current antibiotic classes could create demand for alternatives such as phages, if they demonstrate efficacy in randomized trials.
- Public support for phage therapiesmixed
Non-dilutive funding from MTEC and the Department of War supports AP-SA02 development, but depends on contract conditions and continued government programs 13.
- Regulatory and funding requirementsheadwind
The move to Phase 3 and a future BLA could require considerable resources, and insufficient funding could delay the program.
- Interest in intravenous phage treatmentstailwind
The ability to administer phages intravenously could open future uses beyond the initial indications, if clinical data support it 2.
Competitive position
The antibacterial market includes traditional broad-spectrum antibiotics, which phages compete with as a targeted alternative. The source documents do not explicitly name other competitors, so the competitive analysis remains limited to comparison with standard antibiotics 1.
- Broad-spectrum antibiotics
Standard treatments that can alter the human microbiome and increase susceptibility to opportunistic pathogens, according to the company 1.
- Standard-of-care antibiotics for bacteremia
The base therapy (BAT) with which AP-SA02 is combined in clinical studies, though it does not always achieve cure 1.
- Other phage therapy developers
Companies working on phages could compete for the same indications, but the source documents do not name them.
- Inhaled treatments for P. aeruginosa
Inhaled antibiotics used in chronic pulmonary infections are the alternative AP-PA02 could replace 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Atacuri masive cu drone asupra porturilor ucrainene de la Dunăre. Armata română a ridicat de la sol avioane F-16Moldova 1 — Teleradio-Moldova (MD) · 02 Nov 2026 · RO
- Pierderi record pentru armata rusă în octombrie, potrivit Kievului. Ucraina susține că Moscova nu mai poate înlocui trupeleDigi24 · 01 Nov 2026 · RO
- Alertă de dronă în nordul județului Iași și în Neamț. Armata transmite că a identificat o țintă aeriană la 10 km de granița cu Moldova. Au fost ridicate două avioane F-16 de la Câmpia Turzii.Biziday.ro · 31 Oct 2026 · RO
- Doi spioni chinezi au fost condamnaţi la 30 de ani de închisoare, în SUA. Au încercat să strângă informaţii despre armata americanăAntena 3 CNN · 31 Oct 2026 · RO
- Ce este racheta Bars, „leopardul zăpezilor” ucrainean pe care vrea să-l cumpere armata germanăAntena 3 CNN · 31 Oct 2026 · RO
- Armata Pakistanului manifestă un „optimism prudent” în privința medierii Iran - SUA: „De ce s-ar deplasa mareșalul de două ori?”Digi24 · 30 Oct 2026 · RO
- Disputa rachetelor Patriot: De ce susține NATO că livrează la timp, în timp ce armata ucraineană rămâne fără munițieDefenseRomania.ro · 30 Oct 2026 · RO
- Germania și Ucraina au testat un nou vehicul de luptă fără pilot pentru armata Kievului. Cum va fi folosit pe frontHotNews.ro · 30 Oct 2026 · RO
- Armata bulgară, acuzată că a ignorat dronele rusești care au lovit o navă în Marea Neagră, deși știa de atac cu o oră înainteLibertatea.ro · 30 Oct 2026 · RO
- Cum a rămas Armata fără 300 de mii de metri pătrați de teren și construcții pe care se află un turn de comunicații strategice și cum mai ajunge astăzi la acestaLibertatea.ro · 30 Oct 2026 · RO
- Armata SUA a instalat sisteme de apărare aeriană la reședința lui Trump de la Mar-a-Lago, în FloridaAntena 3 CNN · 30 Oct 2026 · RO
- Fabrica din Rusia care hrănește armata lui Putin, atacată de dronele ucrainene. Uzina produce rații alimentare pentru trupele de pe frontAdevărul · 30 Oct 2026 · RO
- Diplomația poligoanelor: Cum pregătește România armata R. Moldova, de la instruire pe Piranha 3 la căști de protecție antibalistică și exerciții comuneDefenseRomania.ro · 30 Oct 2026 · RO
- Camioanele sovietice din Armata Națională ar putea fi înlocuite cu unele italiene. Nosatîi anunță negocieri cu RomâniaMoldova 1 — Teleradio-Moldova (MD) · 29 Oct 2026 · RO
- SUA: Armata a instalat sisteme de apărare aeriană la reședința lui Trump de la Mar-a-Lago, în FloridaAgerpres · 29 Oct 2026 · RO
- Lituania a decis. Va reintroduce serviciul militar general începând din 2032. Câți tineri vor face armataAntena 3 CNN · 29 Oct 2026 · RO
- Țara baltică în care revine recrutarea generală: din 2032, toți bărbații vor face armata. Care e condiția pentru femeiDigi24 · 29 Oct 2026 · RO
- Armata germană testează capacitățile de război electronic la granița Rusiei. „Domeniul cibernetic nu este încă în război, dar nu mai este nici pace”HotNews.ro · 28 Oct 2026 · RO
- Semnalele de alarmă ale turiștilor au trimis armata italiană în Dolomiți. Ce au găsit militarii în zonele unde se topesc ghețariiAdevărul · 28 Oct 2026 · RO
- Bomba secolului în armata britanică. Secretul șocant descoperit după moartea unuia dintre cei mai faimoși chirurgi militari din EuropaAdevărul · 28 Oct 2026 · RO
SEC filings
- Current report23 Sept 2026Other events · Financial statements and exhibits
- Current report14 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report12 Aug 2026
- Current report12 Aug 2026Results of operations · Financial statements and exhibits
- Current report20 Jul 2026Regulation FD disclosure · Financial statements and exhibits
- Current report20 Jul 2026Departure or appointment of officers · Financial statements and exhibits
- Current report13 Jul 2026Regulation FD disclosure · Financial statements and exhibits
- Current report (amendment)24 Jun 2026Departure or appointment of officers
- Current report23 Jun 2026Other events · Financial statements and exhibits
- Current report16 Jun 2026Shareholder vote
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Armata Pharmaceuticals, Inc. · 25 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Armata Pharmaceuticals, Inc. · 12 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Armata Pharmaceuticals, Inc. · 12 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.